An effective diagnostic strategy to identify BRAF/NRAS MM can allow the development of a subsequent targeted therapy that can improve the prognostic outcomes and therapeutic approaches among advanced MM patients11,16–19. The gene discussed is NRAS; the disease is Miyoshi myopathy.